Interest of Chromogranin A for diagnosis and follow‐up of endocrine tumours
- 22 April 2004
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 60 (5), 644-652
- https://doi.org/10.1111/j.1365-2265.2004.02030.x
Abstract
Objective To determine the interest of Chromogranin A (CgA) determination for diagnosis and follow-up in patients with gastroenteropancreatic endocrine tumours (GEP-ET) and multiple endocrine neoplasia type 1 (MEN-1). patients and methods CgA levels were measured with an immunoradiometric assay in 124 sporadic GEP-ET, 34 MEN-1 and 127 controls. Serial determinations were performed in 56 patients (212 visits). Changes in CgA levels over 25% were considered as significant. results Using a cut-off value of 130 µg/l, established from a receiver-operating characteristic curve, the specificity of CgA was 98·4%, with a sensitivity of 62·9%, higher in secreting than in nonsecreting tumours (73%vs. 45%; P < 0·003) and related to the extent of metastatic spreading (P < 0·001). In nonsecreting tumours, the positive predictive value (PPV) of CgA for the presence of metastases was 100% but the negative predictive value (NPV) was only 50%. In MEN-1, high CgA levels indicated a pancreatic tumour with a 100% specificity but the sensitivity was 59%. During the follow-up, the concordance between CgA and tumour evolution was 80%, whatever the secretory status. In patients with carcinoid tumours, the concordance was higher for CgA than for serotonin (81%vs. 54%; P < 0·001). conclusion Due to its high specificity, CgA determination may help to discriminate the endocrine character of a GEP tumour and to indicate a pancreatic tumour in MEN-1. However, its low NPV in nonsecreting tumours limits its interest for diagnosis and staging. By contrast, serial evaluation of CgA seems of particular interest for the follow-up of GEP-ET tumours.Keywords
This publication has 30 references indexed in Scilit:
- Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomasCancer, 2003
- Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1Journal of Clinical Endocrinology & Metabolism, 1999
- Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumoursJournal of Endocrinology, 1995
- Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunctionJournal of Clinical Endocrinology & Metabolism, 1994
- Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma PatientsActa Oncologica, 1993
- Serum chromogranin A in the diagnosis and follow‐up of neuroendocrine tumors of the gastroenteropancreatic tractWorld Journal of Surgery, 1992
- Peptide Hormones as Tumor Markers in Neuroendocrine Gastrointestinal TumorsActa Oncologica, 1991
- Chromogranin A Storage and SecretionMedicine, 1991
- Effect of ethanol ingestion on postprandial gastric emptying and secretion, biliopancreatic secretions, and duodenal absorption in manDigestive Diseases and Sciences, 1986
- Secretion of Chromogranin A by Peptide-Producing Endocrine NeoplasmsNew England Journal of Medicine, 1986